Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3884 Target Snapshot

Sodium/glucose cotransporter 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,766Compounds
155Assays
12Approved Drugs
2,555.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Sodium/glucose cotransporter 2 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 15 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P31639. Start with type 2 diabetes mellitus, then reuse UniProt P31639 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with type 2 diabetes mellitus, then reuse UniProt P31639 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 15 linked drugs
Open source guide
Disease program
type 2 diabetes mellitus

Sodium/glucose cotransporter 2 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 15 linked drugs remain visible in the same block.

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include BEXAGLIFLOZIN, CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN PROPANEDIOL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 15 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sodium/glucose cotransporter 2 as ChEMBL target CHEMBL3884, mapped to UniProt P31639. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sodium/glucose cotransporter 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3884
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P31639
Sodium/glucose cotransporter 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Sodium/glucose cotransporter 2 is the right protein anchor across sources, using UniProt P31639 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why type 2 diabetes mellitus is currently framed as approved-linked support. It currently carries 15 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameSodium/glucose cotransporter 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP31639
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSodium/glucose cotransporter 2
UniProt AccessionP31639
Component TypeProtein
Sequence Length672 aa

Sodium/glucose cotransporter 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Sodium/glucose cotransporter 2, mapped to UniProt P31639. Sequence length is 672 aa.

Mapped IDP31639
Review nameSodium/glucose cotransporter 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Sodium/glucose cotransporter 2 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
type 2 diabetes mellitus
15 linked drugs · 15 direct · 15 efficacy
Linked drugBEXAGLIFLOZIN
Linked drugCANAGLIFLOZIN
Linked drugDAPAGLIFLOZIN
Linked drugDAPAGLIFLOZIN PROPANEDIOL
Approved-linked Approved
diabetes mellitus
8 linked drugs · 8 direct · 8 efficacy
Linked drugBEXAGLIFLOZIN
Linked drugCANAGLIFLOZIN
Linked drugDAPAGLIFLOZIN
Linked drugDAPAGLIFLOZIN PROPANEDIOL
Approved-linked Approved
type 1 diabetes mellitus
7 linked drugs · 7 direct · 7 efficacy
Linked drugCANAGLIFLOZIN
Linked drugDAPAGLIFLOZIN
Linked drugDAPAGLIFLOZIN PROPANEDIOL
Linked drugEMPAGLIFLOZIN
Approved-linked Approved
heart failure
6 linked drugs · 6 direct · 6 efficacy
Linked drugCANAGLIFLOZIN
Linked drugDAPAGLIFLOZIN
Linked drugDAPAGLIFLOZIN PROPANEDIOL
Linked drugEMPAGLIFLOZIN
Approved-linked Approved
chronic kidney disease
5 linked drugs · 5 direct · 5 efficacy
Linked drugCANAGLIFLOZIN
Linked drugDAPAGLIFLOZIN
Linked drugDAPAGLIFLOZIN PROPANEDIOL
Linked drugEMPAGLIFLOZIN
Approved-linked Approved
nasopharyngeal neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugSOTAGLIFLOZIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include BEXAGLIFLOZIN, CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN PROPANEDIOL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasetype 2 diabetes mellitus
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

12
Approved
1
Phase III
8
Phase II
Assay Mix

Activity Type Distribution

IC502,317.0
KI31.0
EC50207.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1164052 9.52 IC50 0.3 Preclinical
CHEMBL565781 9.52 IC50 0.3 Preclinical
CHEMBL3703868 9.51 IC50 0.308 Preclinical
CHEMBL5288495 9.46 IC50 0.35 Preclinical
CHEMBL3703920 9.44 IC50 0.366 Preclinical
CHEMBL3703908 9.44 IC50 0.366 Preclinical
CHEMBL3703912 9.4 IC50 0.4 Preclinical
CHEMBL3703785 9.36 IC50 0.44 Preclinical
CHEMBL3703921 9.34 IC50 0.46 Clinical
CHEMBL3703855 9.34 IC50 0.454 Preclinical
Distribution

pChEMBL Value Distribution

57
5.0
86
5.5
197
6.0
283
6.5
319
7.0
270
7.5
332
8.0
454
8.5
252
9.0
4
9.5
pChEMBL
Approved Drugs

Approved Drugs

BEXAGLIFLOZIN
CHEMBL1808388
Approved 2023
Properties Compare Identifier
SOTAGLIFLOZIN
CHEMBL3039507
Approved 2019
Properties Compare Identifier
ERTUGLIFLOZIN
CHEMBL1770248
Approved 2017
Properties Compare Identifier
TOFOGLIFLOZIN ANHYDROUS
CHEMBL2110731
Approved 2014
Properties Compare Identifier
EMPAGLIFLOZIN
CHEMBL2107830
Approved 2014
Properties Compare Identifier
IPRAGLIFLOZIN
CHEMBL2018096
Approved 2014
Properties Compare Identifier
DAPAGLIFLOZIN
CHEMBL429910
Approved 2012
Properties Compare Identifier
CANAGLIFLOZIN ANHYDROUS
CHEMBL2048484
Approved 2011
Properties Compare Identifier
Assay Landscape

Assay Landscape

155
Total Assays
1,605
Tested Compounds
3
Assay Types
Binding — 152 assays, 1,605 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 102 1,111 7.3
single protein format 33 169 7.2
assay format 16 324 8.5
cell membrane format 1 1 8.5
Functional — 2 assays, 21 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 20 7.3
cell-free format 1 1 8.7
ADME — 1 assays, 19 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 19 8.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine